Arcutis Biotherapeutics Inc
ARQT
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.97B
Close$
$-28.99
221.6% downside
Current Fair Value
221.6% downsideOvervalued by 221.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.97 Billion |
|---|---|
| Enterprise Value | $3.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.53 |
| Outstanding Shares | 130,522,000 |
Return
| Return on Equity | 12.93% |
|---|---|
| Return on Assets | 5.84% |
| Return on Invested Capital | 11.86% |
Valuation & Multiples
| P/E Ratio | 107.7 |
|---|---|
| PEG | -55.38 |
| Price to Sales | 7.95 |
| Price to Book Ratio | 23.85 |
| Enterprise Value to Revenue | 6.58 |
| Enterprise Value to EBIT | 78.47 |
| Enterprise Value to Net Income | 107 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$118.85 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$141.02 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0842▼ 16.16% |
|---|---|
| Total Calls | 547,200▲ 63.44% |
| Total Puts | 46,100▼ 43.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.88%▲ 2.54% |
|---|---|
| Total Invested | $3.60B▲ 15.33% |
| Investors Holding | 281▲ 3.00% |
ESG Score
No data